Percheron Therapeutics Ltd Asset Resilience Ratio
Percheron Therapeutics Ltd asset resilience ratio. Percheron Therapeutics Ltd (PER) has an Asset Resilience Ratio of 76.79% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Percheron Therapeutics Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Percheron Therapeutics Ltd (2016–2025)
Asset resilience ratio of Percheron Therapeutics Ltd from 2016 to 2025. This chart shows how Percheron Therapeutics Ltd's Asset Resilience Ratio has changed over time. Read PER current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Percheron Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Percheron Therapeutics Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$9.55 Million | 76.79% |
| Total Liquid Assets | AU$9.55 Million | 76.79% |
Asset Resilience Insights
- Very High Liquidity: Percheron Therapeutics Ltd maintains exceptional liquid asset reserves at 76.79% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Percheron Therapeutics Ltd Industry Peers by Asset Resilience Ratio
Compare Percheron Therapeutics Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 29.37% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321 |
Drug Manufacturers - Specialty & Generic | 5.10% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
HPGC Renmintongtai Pharmaceutical Corp
SHG:600829 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Percheron Therapeutics Ltd Asset Resilience Ratio by Year (2016–2025)
Percheron Therapeutics Ltd asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Percheron Therapeutics Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 76.79% | AU$9.55 Million ≈ $6.76 Million |
AU$12.44 Million ≈ $8.80 Million |
-4.96pp |
| 2023-06-30 | 81.76% | AU$10.50 Million ≈ $7.43 Million |
AU$12.84 Million ≈ $9.09 Million |
-0.32pp |
| 2022-06-30 | 82.08% | AU$18.42 Million ≈ $13.03 Million |
AU$22.44 Million ≈ $15.88 Million |
-3.92pp |
| 2021-06-30 | 86.00% | AU$6.02 Million ≈ $4.26 Million |
AU$7.00 Million ≈ $4.95 Million |
+10.15pp |
| 2020-06-30 | 75.85% | AU$4.06 Million ≈ $2.87 Million |
AU$5.35 Million ≈ $3.79 Million |
-2.66pp |
| 2019-06-30 | 78.51% | AU$2.90 Million ≈ $2.05 Million |
AU$3.70 Million ≈ $2.62 Million |
-11.02pp |
| 2018-06-30 | 89.52% | AU$4.30 Million ≈ $3.04 Million |
AU$4.80 Million ≈ $3.40 Million |
+14.62pp |
| 2017-06-30 | 74.91% | AU$1.90 Million ≈ $1.35 Million |
AU$2.54 Million ≈ $1.80 Million |
-- |
| 2016-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$5.33 Million ≈ $3.77 Million |
-- |
About Percheron Therapeutics Ltd
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia. The company's lead asset is ATL1102, an antisense oligonucleotide inhibitor of CD49d, which is in Phase IIb clinical trial for the treatment of Duchenne muscular dystrophy, multiple sclerosis, asthma, and other inflammatory indications. It also devel… Read more